BMC Endocrine Disorders最新文献

{"title":"A J-shaped association between the atherogenic index of plasma and diabetes risk in a Japanese population: a large-scale retrospective cohort study.","authors":"Dong Liu, Mingxing Lou, Yue Tang, Cheng Li, Hao He","doi":"10.1186/s12902-025-01951-y","DOIUrl":"10.1186/s12902-025-01951-y","url":null,"abstract":"<p><strong>Background: </strong>Atherosclerotic dyslipidemia has been linked to an increased risk of type 2 diabetes (T2D). While previous studies have established an association between the atherogenic index of plasma (AIP) and insulin resistance, there is a notable lack of large-scale cohort studies examining the relationship between AIP and the risk of T2D in the general population. Therefore, the present longitudinal study aims to examine the association between AIP and the risk of T2D in a cohort of Japanese adults.</p><p><strong>Methods: </strong>This retrospective cohort study included a total of 15,453 adults. To evaluate the association between the AIP and the risk of developing T2D, hazard ratios (HR) and 95% confidence intervals (CI) were calculated using Cox proportional hazards regression models. Furthermore, potential nonlinear relationships were explored through Cox proportional hazards regression combined with smooth curve fitting techniques.</p><p><strong>Results: </strong>During a mean follow-up period of 6.05 years, 373 adults developed T2D. Elevated AIP was independently associated with a significantly higher risk of T2D after adjusting for potential confounding factors (HR: 2.23, 95% CI: 1.55-3.20, P < 0.0001). Furthermore, a J-shaped relationship between AIP and the incidence of T2D was observed. When AIP levels were below - 0.45, no statistically significant association was found between AIP and T2D risk (HR: 0.35, 95% CI: 0.06-1.95, P = 0.2298). In contrast, AIP levels exceeding this threshold were positively associated with an increased risk of T2D (HR: 2.61, 95% CI: 1.77-3.85, P < 0.0001).</p><p><strong>Conclusion: </strong>The AIP demonstrates a J-shaped relationship with the risk of developing T2D in Japanese adults. Consequently, maintaining AIP levels below the identified threshold (-0.45) may help reduce their chances of developing diabetes.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"25 1","pages":"141"},"PeriodicalIF":2.8,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143047/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Screening accuracy of Single-Point Insulin Sensitivity Estimator (SPISE) for metabolic syndrome: a systematic review and meta-analysis.","authors":"Alireza Azarboo, Parisa Fallahtafti, Sayeh Jalali, Amirhossein Shirinezhad, Ramin Assempoor, Amirhossein Ghaseminejad-Raeini","doi":"10.1186/s12902-025-01957-6","DOIUrl":"10.1186/s12902-025-01957-6","url":null,"abstract":"<p><strong>Background: </strong>Metabolic syndrome (MetS) is a multifactorial condition linked to increased risk of cardiovascular disease and type 2 diabetes. The Single-Point Insulin Sensitivity Estimator (SPISE), a non-invasive index calculated via 600 × HDL-C^0.185 / (TG^0.2 × BMI^1.338), offers a practical alternative. This systematic review and meta-analysis aim to evaluate the accuracy of SPISE as an indicator for MetS.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis following PRISMA guidelines. We searched databases such as MEDLINE, Scopus, Web of Science, and Embase, focusing on studies evaluating SPISE's screening accuracy for MetS. Eligible studies were observational, reporting mean SPISE values and its predictive performance. Meta-analyses were performed using Hedges' g standardized mean differences (SMD) and pooled area under the curve (AUC) estimates.</p><p><strong>Results: </strong>Seven studies comprising 12,919 participants were included, with an age range of 9.2 ± 2.1 to 52.4 ± 11.0. Individuals with MetS had significantly lower SPISE scores than controls (SMD = -0.94, 95% CI: -1.25 to -0.63). The pooled AUC for SPISE as a predictor of MetS was 0.86 (95% CI: 0.83 to 0.90), surpassing other insulin resistance indices like HOMA-IR and the triglyceride/HDL-C ratio. Meta-regression showed that systolic and diastolic blood pressure were potential sources of heterogeneity and age, gender, BMI, waist circumference, fasting blood glucose, triglyceride, and HDL did not contribute to heterogeneity.</p><p><strong>Conclusions: </strong>SPISE is a highly accurate and non-invasive tool for predicting MetS, potentially outperforming traditional indices like HOMA-IR. Its ease of use and precision make it a valuable clinical screening tool, especially in diverse populations.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"25 1","pages":"142"},"PeriodicalIF":2.8,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142846/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating leptin levels in thyroid dysfunction: a systematic review and meta-analysis.","authors":"Shanshan Liu, Jun Ma, Leyuan Zhang, Yanlong Yang, Ziqi Han, Limin Tian","doi":"10.1186/s12902-025-01943-y","DOIUrl":"10.1186/s12902-025-01943-y","url":null,"abstract":"<p><strong>Purpose: </strong>Leptin is an important regulator of energy homeostasis, analogous to thyroid hormone (TH). The purpose of this study was to investigate circulating leptin levels in thyroid dysfunction (TD) patients and the role of TH levels.</p><p><strong>Methods: </strong>The electronic databases PubMed, Embase, Cochrane Library, and Web of Science were independently searched by two researchers, from inception until February 3, 2024, and updated on February 15, 2025. Pooled standardized mean difference (SMD) with a 95% confidence interval (CI) was calculated by the random effects model.</p><p><strong>Results: </strong>Thirty-eight studies reported circulating leptin levels in TD and control with euthyroidism, 4295 subjects were included in total, of which 1277 were hypothyroidism, 540 were hyperthyroidism, and 2478 were control. Compared to euthyroidism, leptin levels were significantly higher in hypothyroidism, and not significantly altered in hyperthyroidism (SMD [95%CI] = 0.71 [0.38, 1.04] and -0.03 [-0.57, 0.51], respectively). The subgroup analysis indicated that, compared to euthyroidism, leptin levels were significantly higher in subjects regardless of overt and subclinical hypothyroidism (SMD [95%CI] = 0.76 [0.25, 1.26] and 0.41 [0.11, 0.70], respectively), and not significantly different in overt hyperthyroidism (SMD [95%CI] = -0.14 [-0.74, 0.45]). Furthermore, when compared to age-, gender-, and body mass index (BMI)-matched euthyroidism, leptin levels were significantly higher in hypothyroidism and had no significant difference in hyperthyroidism (SMD [95%CI] = 0.66 [0.24, 1.07] and -0.43 [-1.13, 0.27], respectively). A total of 16 studies analyzed the correlations between leptin levels and TH levels in TD, 488 were hypothyroidism and 206 were hyperthyroidism. Following correlation analysis, leptin levels displayed a positive correlation with thyroid-stimulating hormone (TSH) levels (r = 0.19) and a negative correlation with triiodothyronine (T3) levels (r = -0.40) in TD.</p><p><strong>Conclusion: </strong>Compared to euthyroidism, circulating leptin levels were significantly higher in hypothyroidism, and not significantly altered in hyperthyroidism. Besides, leptin levels in TD may be directly regulated by TSH and T3 levels, independent of BMI.</p><p><strong>Trial registration: </strong>CRD42024561055.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"25 1","pages":"140"},"PeriodicalIF":2.8,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated estimated pulse wave velocity and the risk of type 2 diabetes in non-obese young adults: a longitudinal cohort study.","authors":"Chunxia Zhang, Li Chen, Ri Liu","doi":"10.1186/s12902-025-01967-4","DOIUrl":"10.1186/s12902-025-01967-4","url":null,"abstract":"<p><strong>Background: </strong>Arterial stiffness (AS), measured by estimated pulse wave velocity (ePWV), is associated with a higher risk of cardiovascular diseases and type 2 diabetes mellitus (T2DM) in older and obese individuals. However, the role of AS as an early predictor of T2DM in non-obese, young adults remains underexplored. Identifying alternative predictors like AS is crucial for detecting diabetes onset in non-obese and younger populations who may not exhibit traditional risk factors such as high body mass index (BMI).</p><p><strong>Methods: </strong>A cohort of 9,543 non-obese participants aged 18-49 years from the NAGALA dataset was followed over a median period of 6.3 years. Cox proportional hazard models were used to assess the association between ePWV and T2DM risk, adjusting for multiple covariates, including age, sex, BMI, alcohol consumption, smoking status, and metabolic markers. Subgroup analyses were conducted to evaluate the stability of the association across different groups. Additionally, ROC curve analysis was performed to assess the predictive power of ePWV in T2DM risk.</p><p><strong>Results: </strong>A total of 110 participants developed T2DM during follow-up. Elevated ePWV was associated with increased T2DM risk (HR 1.36, 95% CI: 1.05-1.75, P = 0.018), even after adjusting for multiple covariates. The ROC analysis demonstrated that the inclusion of ePWV in the predictive model (sex + BMI + diastolic blood pressure (DBP) + ePWV) improved the predictive power for T2DM risk, with AUC values increasing in comparison to the model using sex, BMI and DBP alone (10-year AUC: 0.734 vs. 0.679, P = 0.016). Subgroup analyses showed that the association between ePWV and T2DM risk was consistent across sex, age, alcohol consumption, and smoking status.</p><p><strong>Conclusions: </strong>Elevated ePWV independently correlates with a higher risk of T2DM in non-obese young adults. This study investigates the relationship between elevated arterial stiffness (AS), measured by estimated pulse wave velocity (ePWV), and the risk of developing type 2 diabetes mellitus (T2DM) in non-obese young adults. While AS has been linked to higher T2DM risk in older or obese individuals, this study uniquely focuses on non-obese young adults, a group not typically associated with high diabetes risk. By analyzing data from over 9,500 participants, the research found that even in individuals with a normal body mass index (BMI), higher ePWV is significantly associated with an increased risk of T2DM. This suggests that measuring ePWV could help detect early diabetes risk in people who may not exhibit traditional risk factors, such as high BMI. The findings highlight the importance of vascular health in prevention of diabetes and propose ePWV as a potential tool for early detection in clinical practice.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"25 1","pages":"139"},"PeriodicalIF":2.8,"publicationDate":"2025-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case-control study combined with machine learning techniques to identify key genetic variations in GSK3B that affect susceptibility to diabetic kidney diseases.","authors":"Jinfang Song, Yi Xu, Liu Xu, Tingting Yang, Ya Chen, Changjiang Ying, Qian Lu, Tao Wang, Xiaoxing Yin","doi":"10.1186/s12902-025-01960-x","DOIUrl":"10.1186/s12902-025-01960-x","url":null,"abstract":"<p><p>The role of genetic susceptibility in early warning and precise treatment of diabetic kidney disease (DKD) requires further investigation. A case-control study was conducted to evaluate the predictive effect of GSK3B genetic polymorphisms on the susceptibility to DKD, with the aim of providing a theoretical basis and laboratory rationale for the prediction of the risk of developing DKD in patients with type 2 diabetes mellitus (T2DM). The GSK3B genotyping was performed by SNaPshot method based on Genotype-Tissue Expression database and thousand genomes database to screen tag SNPs. The polymorphisms of GSK3B tag SNPs were statistically analyzed for their effects on DKD susceptibility and clinical indicators. Urinary exosomes from DKD patients were extracted, protein expression levels of GSK3β were detected by ELISA kits, and kinase activity of GSK3β was quantified by kinase activity spectrometry to evaluate the correlation between the gene polymorphisms of GSK3B and the expression levels and activities of GSK3β. A machine learning model was constructed for assessing the efficacy of GSK3B polymorphisms in predicting the risk of developing DKD in patients with T2DM. A total of 800 subjects who met the inclusion and exclusion criteria were included in the case-control study, including 200 healthy control subjects, 300 patients with T2DM and 300 patients with DKD. Genetic analysis identified five tag SNPs (rs60393216, rs3732361, rs2199503, rs1488766, and rs59669360) associated with the susceptibility to DKD. The protein level and activity of GSK3β were significantly elevated in DKD patients. On the other hand, the expression levels and kinase activity of GSK3β in exosomes differed significantly between patients with different genotypes of the GSK3B, suggesting that the effect of GSK3B gene polymorphisms on GSK3β expression and activity may be an important mechanism leading to individual differences in susceptibility to DKD. XG Boost algorithm model identified rs60393216 and rs1488766 as important biomarkers for clinical early warning of DKD.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"25 1","pages":"138"},"PeriodicalIF":2.8,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12139228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144233202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dynamic changes in metabolic syndrome components and chronic kidney disease risk: a population-based prospective cohort study.","authors":"Yue Huang, Rong Fu, Juwei Zhang, Jinsong Zhou, Siting Chen, Zheng Lin, Xiaoxu Xie, Zhijian Hu","doi":"10.1186/s12902-025-01958-5","DOIUrl":"10.1186/s12902-025-01958-5","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the relationships between dynamic changes in metabolic syndrome (MetS) components and chronic kidney disease (CKD) risk.</p><p><strong>Methods: </strong>Data from the UK Biobank, including baseline assessments from 2006 to 2010, repeat assessments in 2012-2013, and linked national health records, were analyzed. MetS components consisted of abdominal obesity, elevated blood pressure (BP), fasting blood glucose (FBG), serum uric acid (SUA), and lipid abnormalities. The Kaplan-Meier method and log-rank test were used to analyze CKD incidence and group differences. Cox regression models assessed the association between dynamic changes in MetS components and CKD risk.</p><p><strong>Results: </strong>The study enrolled 455,060 participants (45.7% male, 18.4% aged 65 years or older) with a median follow-up of 12.68 years. Those with MetS had a significantly higher 10-year CKD cumulative incidence probability of CKD than those without MetS (4.14% VS 1.14%). Multivariate analysis showed all baseline metabolic abnormalities were linked to CKD risk with HRs from 1.40(1.35-1.45) to 1.85 (1.78-1.92), and MetS strongly associated with CKD (HR: 2.31). CKD risk rose with more MetS components and progression stages. Notably, with FBG being the exception, the four MetS components that shifted from normal at baseline to abnormal at follow - up were associated with elevated CKD risk, with HRs (95% CI) ranging from 1.21 (1.00-1.48) to 1.73 (1.34-2.24). Participants with high baseline SUA, even if it normalized at follow - up, still faced a 1.30 - fold higher CKD risk (95% CI: 1.25-1.35), distinct from other components. For those developing one and ≥ 2 new MetS components at follow - up, the CKD risk HRs (95% CI) were 1.49 (1.00-2.35) and 2.26 (1.21-4.24) respectively.</p><p><strong>Conclusion: </strong>MetS and its component changes are significantly associated with CKD risk, in a dose - response pattern. Incorporating SUA into MetS assessments enhances risk identification, especially noting females' higher susceptibility to elevated SUA. Dynamic monitoring of MetS components is crucial for assessing and predicting CKD risk.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"25 1","pages":"137"},"PeriodicalIF":2.8,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12121056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144179855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychological factors and obesity, not thyroid biomarkers, predict thyroid-dependent quality of life in treated hypothyroidism: a cross-sectional study.","authors":"Bence Bakos, Tibor Solymosi, Balázs Szili, Ágnes Vincze, Szilvia Mészáros, Márk Stempler, Richárd Ármós, András Kiss, Anna Bakos, Nikolette Szücs, Péter Reismann, Judit Tőke, Péter Pusztai, Péter Lakatos, István Takács","doi":"10.1186/s12902-025-01962-9","DOIUrl":"10.1186/s12902-025-01962-9","url":null,"abstract":"<p><strong>Background: </strong>A significant number of patients with primary hypothyroidism report persistent symptoms and decreased quality of life (QoL) despite biochemically adequate levothyroxine replacement. Individual variations in thyroxine conversion, autoimmune inflammation, and psychological factors have all been implicated as a potential cause.</p><p><strong>Methods: </strong>In this cross-sectional study we have examined the association of numerous demographic, disease-specific, and laboratory parameters as well as three patient reported outcome measures with thyroid-dependent QoL as measured by the Underactive Thyroid-Dependent Quality of Life Questionnaire. Patients were stringently selected to minimize the confounding effect of comorbidities or inadequate hormone replacement. We used validated questionnaires to assess somatosensory amplification, depression, and symptom number. Determinants of QoL were evaluated using uni- and multivariable linear modeling, and mediation analysis.</p><p><strong>Results: </strong>Our final sample consisted of 157 patients. 70.7% had Hashimoto's, whereas 29.3% had iatrogenic hypothyroidism. Mean age was 49.5 ± 14.5 years, disease duration: 11.2 ± 8.2 years, thyroxine dose: 1.2 ug/kg bodyweight, TSH: 1.8 ± 0.9 mIU/L. Thyroid-specific biomarkers including TSH, FT3, FT4, rT3, SPINA-GD, anti-TPO, and SHBG had no association with thyroid-dependent QoL. Somatosensory amplification was a strong predictor of the presence and perceived bother of the most common hypothyroidism-associated symptoms. In our final multivariable model (r² = 0.31) the factors associated with thyroid-dependent QoL were somatosensory amplification (p = 0.002), BMI (p = 0.021), and depression (p < 0.001).</p><p><strong>Conclusion: </strong>These results suggest that psychological factors, particularly somatosensory amplification, might play a major role in influencing QoL in hypothyroid individuals on adequate levothyroxine replacement. Our findings do not corroborate a significant role for autoimmune inflammation or tissue-level hypothyroidism.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"25 1","pages":"136"},"PeriodicalIF":2.8,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12105179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determining the best dose of lithium carbonate as adjuvant therapy to radioactive iodine for the treatment of hyperthyroidism: a systematic review and meta-analysis.","authors":"Mohamed Abd-ElGawad, Mahmoud Shaaban Abdelgalil, Manar Mabrouk, Sara Adel Abdelkader Saed, Moaz Salama, Ahmed Farid Gadelmawla","doi":"10.1186/s12902-024-01821-z","DOIUrl":"10.1186/s12902-024-01821-z","url":null,"abstract":"<p><strong>Background: </strong>Hyperthyroidism poses challenges, and common treatments like Radioactive Iodine (RAI) have limitations, prompting exploration of adjunctive approaches. This meta-analysis evaluates the combined impact of RAI and Lithium carbonate (LiCO3) on cure rates and thyroid hormone levels.</p><p><strong>Methods: </strong>We systematically searched Cochrane Library, PubMed, Scopus, and Web of Science for studies comparing LiCO3 combined with RAI to RAI alone. Pooled results analyzed cure rates and Free T3/T4 changes. A subgroup analysis was conducted based on LiCO3 dosage and treatment duration, while meta-regression was performed to assess covariates such as the patient's age, RAI dose, and lithium dose. The risk of bias was evaluated using ROB2, ROBINS-1, and NOS, while the statistical analyses were conducted using Revman software 5.4.1.</p><p><strong>Results: </strong>Analysis of 14 studies involving 2047 patients revealed a significantly increased cure rate with RAI and LiCO3 compared to RAI alone (RR 1.12, 95% CI [1.03,1.23], p = 0.01). Subgroup analysis revealed higher cure rates with short-duration intensified doses of LiCO3, while short-duration diluted doses reduced cure rates. No significant differences were noted in euthyroid and hypothyroid states. Changes in free T3 showed no significant difference between the arms at 7 days and the most common time point. A significant decrease in free T4 favored RAI with LiCO3 at 7 days (MD -4.90, 95% CI [-7.91, -1.89], p = 0.001), and the most common time point (MD -3.83, 95% CI [-7.45, -0.20], p = 0.04). Meta-regression analysis indicated better cure rates in older patients (p < 0.001) and lower total lithium doses (p < 0.001).</p><p><strong>Conclusion: </strong>Treatment with RAI combined with LiCO3 significantly enhanced cure rates, particularly when using short-duration intensified doses of LiCO3. Additionally, LiCO3 effectively reduced T4 levels without altering T3 levels. Future research is needed to validate our findings.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"25 1","pages":"135"},"PeriodicalIF":2.8,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100783/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations between pathological features and radioactive iodine-refractory recurrent papillary thyroid carcinoma: with mutation analysis using recurrent samples.","authors":"Thi Nhung Nguyen, Zhanna Mussazhanova, Hirokazu Kurohama, Van Dong Hoang, Ngoc Ha Le, Thi Minh Hanh Ngo, Van Phu Thang Nguyen, Katsuya Matsuda, Yuki Matsuoka, Katsiaryna Tratsiakova, Thi Ngoc Anh Nguyen, Yerkezhan Sailaubekova, Thi Phuong Nguyen, Minh Son Le, Masahiro Nakashima","doi":"10.1186/s12902-025-01954-9","DOIUrl":"10.1186/s12902-025-01954-9","url":null,"abstract":"<p><strong>Background: </strong>Although papillary thyroid carcinomas (PTC) are usually indolent in nature and clinically controllable, two-thirds of metastatic diseases become radioactive iodine-refractory (RAI-R). This study aimed to determine the role of pathological features, BRAF^V600E, TERT promoter (TERT-p), and their combinations on Vietnamese patients with RAI-R recurrent PTC.</p><p><strong>Methods: </strong>This cross-sectional study included 174 cases of locoregional recurrent PTC, including 135 and 39 RAI-R and RAI-avid (RAI-A) cases, respectively. Logistic regression analyses were used to evaluate the associations between pathological features, mutations, and RAI-R with tissues from recurrent lesions.</p><p><strong>Results: </strong>Loss of polarity/loss of cell cohesiveness (LOP/LCC) component was exclusively observed in recurrent cancers in the RAI-R group. RAI-R was associated with BRAF^V600E mutation, TERT-p mutation, BRAF^V600E/TERT-p single mutant (Smut), BRAF^V600E/TERT-p double mutant (Dmut), tall cell component, and mitosis ≥ 2/2 mm² in the unadjusted logistic regression analysis. Multivariable logistic regression analysis revealed that BRAF^V600E mutation and Dmut were independent predictors of RAI-R. The presence of Dmut (odds ratio [OR] = 6.64) was more significantly associated with RAI-R compared with that of Smut (OR = 2.75). There was a marginal association between tall cell > 5%, mitosis count ≥ 2/2 mm² and RAI-R. The combination of BRAF^V600E/tall cell components was the strongest predictor of RAI-R.</p><p><strong>Conclusions: </strong>RAI-R PTC cases were independently associated with BRAF^V600E, Dmut. The association between Dmut and RAI-R PTC was stronger than that between Smut and RAI-R PTC. Future studies should focus on elucidating the role of mitotic count and LOP/LCC in RAI-R PTC.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"25 1","pages":"134"},"PeriodicalIF":2.8,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090457/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144109705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive value of growth hormone and insulin-like growth factor-1 axis for gestational diabetes mellitus: a prospective cohort study.","authors":"Lingling Cui, Yibo Wang, Zhiqian Li, Xiaoli Yang, Huijun Zhou, Zhengya Zhang, Yuting Gao, Linpu Ji, Ruijie Sun, Luying Qin","doi":"10.1186/s12902-025-01953-w","DOIUrl":"10.1186/s12902-025-01953-w","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to explore the role of growth hormone/insulin-like growth factor-1 risk factor axis in gestational diabetes mellitus, as well as to rank independently risk factors.</p><p><strong>Methods: </strong>This was a prospective cohort study conducted between April 2019 and April 2022. The baseline data and serum samples were collected and analyzed from 241 pregnant women during the second trimester. Logistic regression and restricted cubic spline analyses were conducted to assess the relationship between GH and IGF-1 correlated with risk of GDM. Back-propagation artificial neural network (BPNN) and Receiver operating characteristic (ROC) curve analysis were performed to identify the predictive ability of the GH/IGF-1 axis for GDM.</p><p><strong>Results: </strong>The present study found that the higher serum levels of IGF-1 and the lower serum levels of GH in pregnant women were significantly correlated with risk of GDM. GH and IGF-1 were different in both case and control groups(P < 0.05). BPNN analysis identified IGF-1 as accounting for the highest proportion in the ranking of GDM risk prediction weights (up to 25.4%). Furthermore, the area under ROC curve (AUC) value of the GH and IGF-1 combinations reached 0.770 (95%CI:0.707, 0.83).</p><p><strong>Conclusions: </strong>GH (growth hormone) and IGF-1 (insulin-like growth factor 1) are intricately linked to the development of gestational diabetes mellitus (GDM). Disruptions in the GH/IGF-1 axis can trigger insulin resistance, thereby elevating the risk of GDM.</p><p><strong>Trial registration: </strong>Current Controlled Trials: ChiCTR2000028811. Registration Date:20,200,104.</p>","PeriodicalId":9152,"journal":{"name":"BMC Endocrine Disorders","volume":"25 1","pages":"132"},"PeriodicalIF":2.8,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12087125/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144101346","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}